Back to top
more

Illumina (ILMN)

(Real Time Quote from BATS)

$154.69 USD

154.69
1,196,999

+4.93 (3.29%)

Updated Nov 4, 2024 11:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of its products.

Intersect ENT (XENT) Q1 Loss Wider Than Expected, Revenues Top

by Zacks Equity Research

Intersect ENT (XENT) first-quarter revenues improved year over year on increased PROPEL and SINUVA sales.

Phibro (PAHC) Q3 Earnings Beat Estimates, Margins Decline

by Zacks Equity Research

Phibro's (PAHC) fiscal third-quarter revenues improved year over year on growth in Performance Products and Mineral Nutrition segments.

Tandem Diabetes (TNDM) Q1 Net Loss Narrows, Guidance Up

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong international and domestic pump sales and shipment boosted the first-quarter top line.

NuVasive (NUVA) Q1 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

NuVasive's (NUVA) first-quarter revenues improved year over year led by progress in U.S. procedural volumes and international business.

Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Cerner's (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in gross margin.

Exact Sciences (EXAS) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Exact Sciences' (EXAS) first-quarter 2021 revenues improved year over year led by growth in Precision Oncology, COVID-19 testing and Screening revenues.

PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) first-quarter results benefit from strong segmental performance.

Globus Medical (GMED) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Globus Medical's (GMED) first-quarter 2021 revenues improved year over year on strength in Enabling Technologies and U.S. Spine.

AmerisourceBergen (ABC) Q2 Earnings Beat, Revenues Miss

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal second-quarter results benefit from segmental growth.

Zimmer Biomet (ZBH) Q1 Earnings Top, Operating Margin Up

by Zacks Equity Research

Zimmer Biomet's (ZBH) core hip and S.E.T. business registers growth in the reported quarter.

CVS Health (CVS) Q1 Earnings Beat Estimates, EPS View Up

by Zacks Equity Research

CVS Health's (CVS) revenues across all the three operating segments improve in Q1. Increased guidance amid the pandemic scenario is another positive.

QIAGEN (QGEN) Q1 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.

Hill-Rom (HRC) Q2 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Hill-Rom's (HRC) second-quarter revenues improved year over year on continued recovery across all three business segments as well as expanded demand for critical care products.

Illumina (ILMN) Q1 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Illumina (ILMN) exhibits an impressive performance by its Instruments segment in the first quarter of 2021 despite pandemic-led business disruptions.

Illumina (ILMN) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 38.97% and 0.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Illumina (ILMN) This Earnings Season?

by Zacks Equity Research

Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is likely to have gained during the first quarter on the back of robust performance of the sequencing consumable segment.

Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BMY vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

BMY vs. ILMN: Which Stock Is the Better Value Option?

Company News for Apr 7, 2021

by Zacks Equity Research

Companies in The News Are: ILMN, NVAX, MRNA, BP.

Illumina (ILMN) Preliminary Q1 Revenues Rebound, '21 View Up

by Zacks Equity Research

Illumina's (ILMN) revenue improvement in the first quarter is likely to have been boosted by on-going business recovery.

Illumina (ILMN) Moves 4.1% Higher: Will This Strength Last?

by Zacks Equity Research

Illumina (ILMN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Illumina's (ILMN) Grail Merger in Trouble as FTC Files Suit

by Zacks Equity Research

According to FTC, the Illumina (ILMN) and Grail merger will diminish the scope of innovation in the U.S. market for MCED tests.

Why You Should Hold on to Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of products.